Case Study 20.1 — AquaSense

A composite, illustrative case. Dr. Priya Raman and AquaSense are composites built to teach; the SBIR structures, phases, and dual review are real. Verify current specifics at SBIR.gov and the relevant agency.

The founder and the technology

Dr. Priya Raman leads AquaSense, a six-person startup developing a low-cost, real-time sensor that detects water-quality problems for small utilities and farms — buyers who can't afford the expensive monitoring big systems use and who currently rely on slow, periodic lab testing. The technology is promising but unproven at low cost in real conditions, and AquaSense has no revenue yet. Priya needs money to de-risk the technology — and she does not want to sell a big equity stake to investors this early. SBIR is made for exactly this moment: non-dilutive funding to fund the riskiest R&D without giving up the company. But Priya knows the program's central demand — she must pass both tests, technical and commercial — and she builds her whole campaign around that.

Decision 1 — SBIR vs. STTR, and eligibility (Sections 20.1, 20.3)

AquaSense has its own engineers and lab space and can do the core R&D in-house, so SBIR (not STTR) fits: it's simpler and keeps the work and budget in the company. Priya first confirms eligibility — AquaSense is a small, American-owned for-profit within the size limit, and she checks the current ownership rules to be sure her early investors' stake doesn't disqualify the company. Eligibility is a binary gate (Chapter 19); she clears it before investing effort.

Decision 2 — The right agency, chosen not sprayed (Section 20.5)

AquaSense's sensor touches several agencies' missions — NSF (a sensing innovation), USDA (agricultural water), the EPA (environmental monitoring). A weaker founder might send near-identical proposals to all three. Priya instead chooses by fit and commercialization logic: the EPA's water-quality mission aligns tightly with her actual target customers (small utilities), so she targets there first, frames the innovation around that mission, and keeps USDA in reserve as a different application (farms) for a future cycle. She emails the agency's SBIR program manager to confirm fit before writing — converting the program manager into strategic intelligence.

Decision 3 — Designing Phase I to feed Phase II (Section 20.2)

Priya scopes Phase I around the make-or-break feasibility question: can the low-cost sensor detect the target contaminants accurately and reliably in real water conditions? She does not try to build the finished product; she designs the minimum work to prove the core concept — and she writes 2–4 specific, testable technical objectives that, if met, justify a Phase II. Critically, she also begins customer discovery during Phase I, interviewing small utilities and farm operators, so her commercialization case will rest on real conversations, not guesses. Phase I is built to produce exactly what a strong Phase II will need: feasibility data and a grounded market case.

Decision 4 — Passing both tests (Section 20.4)

Priya writes the proposal as an integrated investment case, not a science paper with a sales pitch stapled on:

  • Technical merit: the innovation, the soundness of the approach, the feasibility plan, the qualified team (Chapter 9).
  • Commercial potential: a commercialization plan built from real evidence — the market sized bottom-up from how many small utilities and farms exist and what they'd pay; named customers she has actually interviewed; an honest comparison against periodic lab testing and incumbent sensor vendors; the IP position; a path from prototype to first pilot sales; and a Phase III financing plan (a later seed round, made less dilutive by the federal validation, plus early pilot revenue).

The commercial opportunity motivates the technical objectives ("we must prove low-cost accuracy because the market requires an affordable sensor"), so the two halves read as one argument.

What happened, and the climb

AquaSense's Phase I is funded — the reviewers see both a feasible technology and a founder who clearly understands her market. Phase I proves the concept and deepens Priya's customer relationships. She then wins Phase II on the strength of the Phase I data and a now-serious commercialization plan, funding a deployable prototype, manufacturing hardening, and pilots with the very customers she's been cultivating. Meanwhile she lines up Phase III financing so AquaSense reaches the market on non-SBIR money. The non-dilutive grants carried the company through its riskiest years; by the time Priya raises equity, AquaSense has a working prototype, pilot customers, and federal validation — so she gives up far less of the company than she would have raising that capital at the idea stage.

What this case teaches

  1. Both tests, always. Priya's funding came from pairing rigorous feasibility with a real, evidenced commercialization case — neither alone would have won.
  2. The ladder is planned from the start. Phase I was designed to feed Phase II, and commercialization work began in Phase I, not after.
  3. Choose the agency; don't spray. One tightly-matched proposal to the EPA beat three generic ones to plausible agencies.
  4. SBIR is a financing strategy. Non-dilutive funding de-risked the technology and preserved equity — the founder's-eye reason SBIR is so prized.

🔄 Retrieve: Without rereading, name (a) why AquaSense chose SBIR over STTR, and (b) two features that made Priya's commercialization plan credible rather than an afterthought. (Answers above.)